Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D A Berry

Showing results (71-80 of 89) with videos related to

Pageof 9
Sort By:
Cytometry|December 15, 1995
Flow cytometry in node-positive breast cancer: cancer and leukemia group B protocol 8869T E Kute, Y Quadri, H Muss, et al.
Clinical Pharmacology and Therapeutics|July 1, 1989
Identification of drug interactions by meta-analysis of premarketing trials: the effect of smoking on the pharmacokinetics and dosage requirements for flecainide acetateJ L Holtzman, C E Weeks, D C Kvam, et al.
Bone Marrow Transplantation|March 7, 1998
Reduced mortality following bone marrow transplantation for breast cancer with the addition of peripheral blood progenitor cells is due to a marked reduction in veno-occlusive disease of the liverD C Fisher, J J Vredenburgh, W P Petros, et al.
British Journal of Cancer|January 28, 2010
Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancerT Hamaoka, C M Costelloe, J E Madewell, et al.
Annals of Emergency Medicine|September 28, 2001
Monitoring a clinical trial conducted under the Food and Drug Administration regulations allowing a waiver of prospective informed consent: the diaspirin cross-linked hemoglobin traumatic hemorrhagic shock efficacy trialR J Lewis, D A Berry, H Cryer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 1999
Dose-response trial of megestrol acetate in advanced breast cancer: cancer and leukemia group B phase III study 8741J Abrams, J Aisner, C Cirrincione, et al.
The New England Journal of Medicine|May 5, 1994
c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancerH B Muss, A D Thor, D A Berry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2000
HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancerD A Berry, H B Muss, A D Thor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1999
Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642M E Costanza, R B Weiss, I C Henderson, et al.
Journal of the National Cancer Institute|September 25, 1998
erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancerA D Thor, D A Berry, D R Budman, et al.
Pageof 9

Showing results (71-80 of 89) with videos related to

Sort By:
Pageof 9
Cytometry|December 15, 1995
Flow cytometry in node-positive breast cancer: cancer and leukemia group B protocol 8869T E Kute, Y Quadri, H Muss, et al.
Clinical Pharmacology and Therapeutics|July 1, 1989
Identification of drug interactions by meta-analysis of premarketing trials: the effect of smoking on the pharmacokinetics and dosage requirements for flecainide acetateJ L Holtzman, C E Weeks, D C Kvam, et al.
Bone Marrow Transplantation|March 7, 1998
Reduced mortality following bone marrow transplantation for breast cancer with the addition of peripheral blood progenitor cells is due to a marked reduction in veno-occlusive disease of the liverD C Fisher, J J Vredenburgh, W P Petros, et al.
British Journal of Cancer|January 28, 2010
Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancerT Hamaoka, C M Costelloe, J E Madewell, et al.
Annals of Emergency Medicine|September 28, 2001
Monitoring a clinical trial conducted under the Food and Drug Administration regulations allowing a waiver of prospective informed consent: the diaspirin cross-linked hemoglobin traumatic hemorrhagic shock efficacy trialR J Lewis, D A Berry, H Cryer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 1999
Dose-response trial of megestrol acetate in advanced breast cancer: cancer and leukemia group B phase III study 8741J Abrams, J Aisner, C Cirrincione, et al.
The New England Journal of Medicine|May 5, 1994
c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancerH B Muss, A D Thor, D A Berry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2000
HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancerD A Berry, H B Muss, A D Thor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1999
Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642M E Costanza, R B Weiss, I C Henderson, et al.
Journal of the National Cancer Institute|September 25, 1998
erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancerA D Thor, D A Berry, D R Budman, et al.
Pageof 9